Results 41 to 50 of about 27,020 (235)

A history of pharmacoepidemiology

Therapies, 2019
Pharmacoepidemiology, in the sense of the study of the reciprocal interactions between drugs and populations, was probably conceived far before being named so. However, the modern era started in 1985 with the birth of the International society of pharmacoepidemiology and the development of specific methodological approaches and large databases.
openaire   +3 more sources

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

The 2nd Euro-Asian Congress of Pharmacoepidemiology: Non-Communicable Diseases as a Threat to Sustainable Development

Journal of Pharmacoeconomics and Pharmaceutical Management, 2023
The 2nd Euro-Asian congress of pharmacoepidemiology (EAPEC 2019) was held in Tehran, Iran, November 13rd–15th, 2019[1]. The congress was organized by the school of pharmacy of Shahid Beheshti University of Medical Sciences (SMBU), and supported by Iran ...
Nazila Yousefi, Farzad Peiravian
doaj  

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care

British Journal of Clinical Pharmacology, EarlyView.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety).
Elise J. Heesbeen, Patrick C. Souverein, Eibert R. Heerdink, Elisabeth Y. Bijlsma, Lucianne Groenink   +4 more
wiley   +1 more source

Shaping the future of pharmacoepidemiology in France: recommendations from the SFPT Pharmacoepidemiology Working Group [PDF]

International audienceThe drug authorization process is shifting towards a policy aimed at shortening time-to-market. While this policy facilitates early access to new treatments, it can also result in potentially insufficient knowledge of both efficacy ...
Grimaldi, Lamiae, Bezin, Julien, Kaguelidou, Florentia, Soeiro, Thomas, Dolladille, Charles, Lafaurie, Margaux, Montastruc, François, Pariente, Antoine, Khouri, Charles, Morin, Lucas, Allouchery, Marion, Scailteux, Lucie-Marie, Faillie, Jean-Luc, Béné, Johana, Largeau, Bérenger   +14 more
core   +1 more source

Literature Review of Safety Event Reporting in Observational Studies: Challenges Extrapolating across Comparable Products

Pharmacoepidemiology, 2023
Nirmatrelvir/ritonavir (PAXLOVIDTM, Pfizer) is an anti-infective inhibiting CYP3A4 indicated for the treatment of COVID-19 in adults at increased risk of severe COVID-19. As a newly approved product, PAXLOVID has limited safety information regarding rare
Heather A. Ward, Bao-Anh Nguyen-Khoa, Robert Massouh   +2 more
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska, Izak A. R. Yasrebi‐de Kom, Nicolette F. de Keizer, Dave A. Dongelmans, on behalf of the RESCUE Study group, Merijn C. Reuland, Irma M. Rigter, Peter F. Schutte, Ilona T. Spaan, Dorieke van Balen, Stefaan Hendriks, Petronella E. Deetman, Cedric Lau, Wytze J. Vermeijden, Marieke G. J. Schouten, Joost B. Masselink, Peter E. Spronk, Marnix Kuindersma, Hendrikus J. M. van Kan, Anne Wellink, Abraham J. Valkenburg, Andre Wieringa, Walter M. van den Bergh, Maurits H. Renes, Wouter Bult, Frouke M. Engelaer, Nienke van Rein, Martijn Hoeksema, Janneke M. van den Broek, Elsbeth Wesselink, Ilse M. Purmer, Thomas Ottens, Bertha E. Bosma, Sjoerd H. W. van Bree, Barbara Festen, Hendrick J. W. Lammers, Rob J. Bosman, Rogier M. Determann, Eric J. F. Franssen, Attila Karakus, Lenneke. E. M. Haas, Freek van Gorp, Dylan W. de Lange, Maaike A. Sikma, Esther V. Uijtendaal   +44 more
wiley   +1 more source

Cost Estimations of Managing Adverse Drug Reactions in Hospitalized Patients: A Systematic Review of Study Methods and Their Influences

Pharmacoepidemiology, 2023
This study aimed to systematically review and explore the impact of study methods on the cost of managing adverse drug reactions (ADRs) among hospitalized patients to guide policymakers and researchers.
Siti Fauziah Abu, Asrul Akmal Shafie, Haarathi Chandriah   +2 more
doaj   +1 more source